Related references
Note: Only part of the references are listed.The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative
Rachel Yung et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Lymph node infiltration, parallel metastasis and treatment success in breast cancer
Jutta Engel et al.
BREAST (2019)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Eleftherios P. Mamounas et al.
LANCET ONCOLOGY (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial
M Gnant et al.
CANCER RESEARCH (2018)
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni et al.
LANCET ONCOLOGY (2018)
Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry
Dieter Hoelzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al.
NATURE (2017)
Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
Angela DeMichele et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
Gretchen L. Gierach et al.
JAMA ONCOLOGY (2017)
Genomic Evolution of Breast Cancer Metastasis and Relapse
Lucy R. Yates et al.
CANCER CELL (2017)
Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial
Maria Ekholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
M. Dowsett et al.
LANCET (2015)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
Jack Cuzick et al.
LANCET ONCOLOGY (2015)
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer
Debora de Melo Gagliato et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
Andrea Veronesi et al.
BMC CANCER (2010)
Distant metastases do not metastasize
Dieter Hoelzel et al.
CANCER AND METASTASIS REVIEWS (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Breast cancer tumor growth estimated through mammography screening data
Harald Weedon-Fekjaer et al.
BREAST CANCER RESEARCH (2008)
Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer
Lars E. Rutqvist et al.
ACTA ONCOLOGICA (2007)
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
K Metcalfe et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Delayed adjuvant tamoxifen:: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
T Delozier et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
